Hyperfine, Inc. (NASDAQ:HYPR) Receives Consensus Rating of “Hold” from Brokerages

Hyperfine, Inc. (NASDAQ:HYPR) has been assigned an average recommendation of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $2.0333.

Several research firms recently issued reports on HYPR. BTIG Research reissued a “buy” rating and issued a $2.00 price target on shares of Hyperfine in a research report on Thursday, August 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperfine in a research note on Friday, July 17th. Finally, B. Riley Financial reissued a “buy” rating and set a $1.60 price objective (down from $2.00) on shares of Hyperfine in a report on Monday, August 10th.

Hyperfine Trading Up 0.5%

Shares of HYPR stock opened at $0.79 on Friday. Hyperfine has a fifty-two week low of $0.78 and a fifty-two week high of $2.22. The company has a debt-to-equity ratio of 0.36, a quick ratio of 5.45 and a current ratio of 6.15. The stock has a 50 day simple moving average of $0.93 and a two-hundred day simple moving average of $1.20. The company has a market cap of $83.79 million, a P/E ratio of -2.08 and a beta of 1.41.

Hyperfine (NASDAQ:HYPR) last released its earnings results on Thursday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Hyperfine had a negative net margin of 210.75% and a negative return on equity of 97.88%. The company had revenue of $3.90 million for the quarter, compared to the consensus estimate of $4.13 million. Research analysts forecast that Hyperfine will post -0.34 earnings per share for the current year.

Institutional Trading of Hyperfine

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Hyperfine by 5.7% during the third quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock worth $5,092,000 after purchasing an additional 190,136 shares during the last quarter. Catalio Capital Management LP boosted its stake in shares of Hyperfine by 92.8% in the 4th quarter. Catalio Capital Management LP now owns 1,320,041 shares of the company’s stock worth $1,293,000 after buying an additional 635,500 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Hyperfine by 21.4% in the fourth quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock valued at $799,000 after acquiring an additional 143,975 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Hyperfine by 100.2% during the first quarter. Renaissance Technologies LLC now owns 730,233 shares of the company’s stock valued at $789,000 after acquiring an additional 365,490 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Hyperfine during the second quarter valued at approximately $419,000. Institutional investors own 15.03% of the company’s stock.

Hyperfine Company Profile

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.